HomeAI · summaries
Storia in 3 fonti
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with…
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line…
- ·
benzinga.com
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer - Verastem (NASDAQ:VSTM)
Verastem updated RAMP 205 data showed 86% six-month survival in metastatic pancreatic cancer and continued tumor shrinkage.
